Extracellular vesicles as biomarkers and therapeutic targets in breast cancer

Anticancer Research

Volumn 35, Issue 12, 2015, Pages 6379-6390

  Sadovska, Lilite ^a   Eglitis, Janis ^b   Line, Aija ^a  

^a LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

^b UNIVERSITY OF LATVIA   (Latvia)

Author keywords

Biomarkers; Breast cancer; Exosomes; Extracellular vesicles; Liquid biopsy; Microvesicles; Review

Indexed keywords

MESSENGER RNA; MICRORNA; ONCOPROTEIN; PIWI INTERACTING RNA; RIBOSOME RNA; TRANSFER RNA; TUMOR MARKER;

BIOGENESIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CLINICAL DECISION MAKING; EPIDERMAL GROWTH FACTOR RECEPTOR 2 BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EXOSOME; GENE AMPLIFICATION; GENE EXPRESSION; HEALTH CARE NEED; HUMAN; MULTIVESICULAR BODY; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; TRIPLE NEGATIVE BREAST CANCER; TUMOR PROMOTION; BREAST TUMOR; FEMALE; METABOLISM; PATHOLOGY;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; EXTRACELLULAR VESICLES; FEMALE; HUMANS;

EID: 84949426710     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, and Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 Lyon, France: International Agency for Research on Cancer, 2013.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49: 1374-1403, 2013.
3. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA: a cancer journal for clinicians 63: 11-30, 2013.
4. Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70, 2012.
5. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B and Senn HJ: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 22: 1736-1747, 2011.
6. Hammond ME, Hayes DF and Wolff AC: Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29: e458, 2011.
7. Prat A and Perou CM: Deconstructing the molecular portraits of breast cancer. Molecular oncology 5: 5-23, 2011.
8. Yanez-Mo M, Siljander PR, Andreu Z, Zavec AB, Borras FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colas E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Kramer-Albers EM, Laitinen S, Lasser C, Lener T, Ligeti E, Line A, Lipps G, Llorente A, Lotvall J, Mancek-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-'t Hoen EN, Nyman TA, O'Driscoll L, Olivan M, Oliveira C, Pallinger E, Del Portillo HA, Reventos J, Rigau M, Rohde E, Sammar M, Sanchez-Madrid F, Santarem N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH and De Wever O: Biological properties of extracellular vesicles and their physiological functions. Journal of extracellular vesicles 4: 27066, 2015.
9. Robbins PD and Morelli AE: Regulation of immune responses by extracellular vesicles. Nature reviews Immunology 14: 195-208, 2014.
10. Kahlert C and Kalluri R: Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) 91: 431-437, 2013.
11. Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, and Skog J: Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. NatCommun 2: 180, 2011.
12. Hessvik NP, Phuyal S, Brech A, Sandvig K, and Llorente A: Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. BiochimBiophysActa 1819: 1154-1163, 2012.
13. Llorente A, Skotland T, Sylvanne T, Kauhanen D, Rog T, Orlowski A, Vattulainen I, Ekroos K, and Sandvig K: Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. BiochimBiophysActa 1831: 1302-1309, 2013.
14. Eldh M, Bagge RO, Lasser C, Svanvik J, Sjostrand M, Mattsson J, Lindner P, Choi DS, Gho YS, and Lotvall J: MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma. BMC Cancer 14: 962, 2014.
15. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, and Lyden D: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature medicine 18: 883-891, 2012.
16. Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, Zheng Y, Hoshino A, Brazier H, Xiang J, Williams C, Rodriguez-Barrueco R, Silva JM, Zhang W, Hearn S, Elemento O, Paknejad N, Manova-Todorova K, Welte K, Bromberg J, Peinado H, and Lyden D: Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res 24: 766-769, 2014.
17. Sadovska L, Bajo CS, Kalnia Z, and Lin A: Biodistribution, Uptake and Effects Caused by Cancer-derived Extracellular Vesicles. Journal of Circulating Biomarkers 4: 1-15, 2015.
18. Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, and Di Leo A: Challenges in the management of advanced, ERpositive, HER2-negative breast cancer. Nature reviews Clinical oncology 2015.
19. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. Ontario health technology assessment series 10: 1-57, 2010.
20. O'Shaughnessy J: Extending survival with chemotherapy in metastatic breast cancer. The oncologist 10(Suppl 3): 20-29, 2005.
21. Markopoulos C: Overview of the use of Oncotype DX((R)) as an additional treatment decision tool in early breast cancer. Expert review of anticancer therapy 13: 179-194, 2013.
22. Zanotti L, Bottini A, Rossi C, Generali D, and Cappelletti MR: Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 35: 8461-8470, 2014.
23. Lavaud P and Andre F: Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC medicine 12: 132, 2014.
24. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, and Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. The oncologist 14: 320-368, 2009.
25. Pernas Simon S: Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications. Therapeutic advances in medical oncology 6: 210-221, 2014.
26. Vu T and Claret FX: Trastuzumab: updated mechanisms of action and resistance in breast cancer. Frontiers in oncology 2: 62, 2012.
27. Pohlmann PR, Mayer IA, and Mernaugh R: Resistance to Trastuzumab in Breast Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 7479-7491, 2009.
28. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, and Maihle NJ: Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer research 69: 2191-2194, 2009.
29. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, and Baselga J: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. Journal of the National Cancer Institute 99: 628-638, 2007.
30. Green AR, Barros FF, Abdel-Fatah TM, Moseley P, Nolan CC, Durham AC, Rakha EA, Chan S, and Ellis IO: HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast cancer research and treatment 145: 33-44, 2014.
31. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, and Parsons R: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer research 65: 2554-2559, 2005.
32. Fang L, Barekati Z, Zhang B, Liu Z, and Zhong X: Targeted therapy in breast cancer: what's new Swiss medical weekly 141: w13231, 2011.
33. Schneeweiss A, Chia S, Hegg R, Tausch C, Deb R, Ratnayake J, McNally V, Ross G, Kiermaier A, and Cortes J: Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab-and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study. Breast cancer research: BCR 16: R73, 2014.
34. Minami CA, Chung DU, and Chang HR: Management options in triple-negative breast cancer. Breast cancer: basic and clinical research 5: 175-199, 2011.
35. Criscitiello C, Azim HA, Jr., Schouten PC, Linn SC, and Sotiriou C: Understanding the biology of triple-negative breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 23(Suppl 6): vi13-18, 2012.
36. Wahba HA and El-Hadaad HA: Current approaches in treatment of triple-negative breast cancer. Cancer Biology & Medicine 12: 106-116, 2015.
37. Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, and Ueno NT: Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype Oncotarget 6: 12890-12908, 2015.
38. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, and Pietenpol JA: Identification of human triplenegative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation 121: 2750-2767, 2011.
39. Crown J, O'Shaughnessy J, and Gullo G: Emerging targeted therapies in triple-negative breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology /ESMO 23(Suppl 6): vi56-65, 2012.
40. Humbert O, Riedinger JM, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V, Kanoun S, Coutant C, Fumoleau P, Cochet A, and Brunotte F: Identification of biomarkers including 18FDG-PET/CT for early prediction of response to neoadjuvant chemotherapy in Triple Negative Breast Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 2015.
41. Millis SZ, Gatalica Z, Winkler J, Vranic S, Kimbrough J, Reddy S, and O'Shaughnessy JA: Predictive Biomarker Profiling of >6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications. Clinical breast cancer 2015.
42. Gould SJ and Raposo G: As we wait: coping with an imperfect nomenclature for extracellular vesicles. Journal of extracellular vesicles 2: 2013.
43. Ronquist G: Prostasomes: Their Characterisation: Implications for Human Reproduction: Prostasomes and Human Reproduction. Advances in experimental medicine and biology 868: 191-209, 2015.
44. Minciacchi VR, You S, Spinelli C, Morley S, Zandian M, Aspuria PJ, Cavallini L, Ciardiello C, Reis Sobreiro M, Morello M, Kharmate G, Jang SC, Kim DK, Hosseini-Beheshti E, Tomlinson Guns E, Gleave M, Gho YS, Mathivanan S, Yang W, Freeman MR and Di Vizio D: Large oncosomes contain distinct protein cargo and represent a separate functional class of tumorderived extracellular vesicles. Oncotarget 6: 11327-11341, 2015.
45. Ostman S, Taube M and Telemo E: Tolerosome-induced oral tolerance is MHC dependent. Immunology 116: 464-476, 2005.
46. Maguire CA, Balaj L, Sivaraman S, Crommentuijn MH, Ericsson M, Mincheva-Nilsson L, Baranov V, Gianni D, Tannous BA, Sena-Esteves M, Breakefield XO and Skog J: Microvesicleassociated AAV vector as a novel gene delivery system. Molecular therapy: the journal of the American Society of Gene Therapy 20: 960-971, 2012.
47. El AS, Mager I, Breakefield XO and Wood MJ: Extracellular vesicles: biology and emerging therapeutic opportunities. NatRevDrug Discov 12: 347-357, 2013.
48. Kalra H, Simpson RJ, Ji H, Aikawa E, Altevogt P, Askenase P, Bond VC, Borras FE, Breakefield X, Budnik V, Buzas E, Camussi G, Clayton A, Cocucci E, Falcon-Perez JM, Gabrielsson S, Gho YS, Gupta D, Harsha HC, Hendrix A, Hill AF, Inal JM, Jenster G, Kramer-Albers EM, Lim SK, Llorente A, Lotvall J, Marcilla A, Mincheva-Nilsson L, Nazarenko I, Nieuwland R, Nolte-'t Hoen EN, Pandey A, Patel T, Piper MG, Pluchino S, Prasad TS, Rajendran L, Raposo G, Record M, Reid GE, Sanchez-Madrid F, Schiffelers RM, Siljander P, Stensballe A, Stoorvogel W, Taylor D, Thery C, Valadi H, van Balkom BW, Vazquez J, Vidal M, Wauben MH, Yanez-Mo M, Zoeller M and Mathivanan S: Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoSBiol 10: e1001450, 2012.
49. Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, Aradi B, Laszlo V, Pallinger E, Pap E, Kittel A, Nagy G, Falus A, and Buzas EI: Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cellular and molecular life sciences: CMLS 68: 2667-2688, 2011.
50. Thery C, Ostrowski M, and Segura E: Membrane vesicles as conveyors of immune responses. NatRevImmunol 9: 581-593, 2009.
51. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, and Geuze HJ: B lymphocytes secrete antigenpresenting vesicles. The Journal of experimental medicine 183: 1161-1172, 1996.
52. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, and Sixma JJ: Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 94: 3791-3799, 1999.
53. Wickman G, Julian L and Olson MF: How apoptotic cells aid in the removal of their own cold dead bodies. Cell death and differentiation 19: 735-742, 2012.
54. Weigert A, Johann AM, von Knethen A, Schmidt H, Geisslinger G and Brune B: Apoptotic cells promote macrophage survival by releasing the antiapoptotic mediator sphingosine-1-phosphate. Blood 108: 1635-1642, 2006.
55. Atkin-Smith GK, Tixeira R, Paone S, Mathivanan S, Collins C, Liem M, Goodall KJ, Ravichandran KS, Hulett MD and Poon IK: A novel mechanism of generating extracellular vesicles during apoptosis via a beads-on-a-string membrane structure. Nature communications 6: 7439, 2015.
56. Poon IK, Chiu YH, Armstrong AJ, Kinchen JM, Juncadella IJ, Bayliss DA and Ravichandran KS: Unexpected link between an antibiotic, pannexin channels and apoptosis. Nature 507: 329-334, 2014.
57. Berda-Haddad Y, Robert S, Salers P, Zekraoui L, Farnarier C, Dinarello CA, Dignat-George F and Kaplanski G: Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1alpha. Proceedings of the National Academy of Sciences of the United States of America 108: 20684-20689, 2011.
58. Hanayama R, Tanaka M, Miyasaka K, Aozasa K, Koike M, Uchiyama Y and Nagata S: Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 304: 1147-1150, 2004.
59. Colombo M, Moita C, van NG, Kowal J, Vigneron J, Benaroch P, Manel N, Moita LF, Thery C and Raposo G: Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. JCell Sci 126: 5553-5565, 2013.
60. Bobrie A, Colombo M, Krumeich S, Raposo G and Thery C: Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation. Journal of extracellular vesicles 1: 2012.
61. Xu R, Greening DW, Rai A, Ji H and Simpson RJ: Highlypurified exosomes and shed microvesicles isolated from the human colon cancer cell line LIM1863 by sequential centrifugal ultrafiltration are biochemically and functionally distinct. Methods 2015.
62. Rana S, Claas C, Kretz CC, Nazarenko I, and Zoeller M: Activation-induced internalization differs for the tetraspanins CD9 and Tspan8: Impact on tumor cell motility. The international journal of biochemistry & cell biology 43: 106-119, 2011.
63. Rana S, Yue S, Stadel D, and Zoller M: Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. The international journal of biochemistry & cell biology 44: 1574-1584, 2012.
64. Hugel B, Martinez MC, Kunzelmann C, and Freyssinet JM: Membrane microparticles: two sides of the coin. Physiology (Bethesda) 20: 22-27, 2005.
65. Weigert A, Jennewein C, and Brune B: The liaison between apoptotic cells and macrophages-the end programs the beginning. Biological chemistry 390: 379-390, 2009.
66. Mizutani K, Terazawa R, Kameyama K, Kato T, Horie K, Tsuchiya T, Seike K, Ehara H, Fujita Y, Kawakami K, Ito M, and Deguchi T: Isolation of prostate cancer-related exosomes. Anticancer Res 34: 3419-3423, 2014.
67. Ji H, Chen M, Greening DW, He W, Rai A, Zhang W and Simpson RJ: Deep sequencing of RNA from three different extracellular vesicle (EV) subtypes released from the human LIM1863 colon cancer cell line uncovers distinct miRNAenrichment signatures. PLoS One 9: e110314, 2014.
68. Ekstrom K, Valadi H, Sjostrand M, Malmhall C, Bossios A, Eldh M and Lotvall J: Characterization of mRNA and microRNA in human mast cell-derived exosomes and their transfer to other mast cells and blood CD34 progenitor cells. JExtracellVesicles 1: 2012.
69. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ and Lotvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. NatCell Biol 9: 654-659, 2007.
70. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P and Ratajczak MZ: Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 20: 847-856, 2006.
71. Nolte-'t Hoen EN, Buermans HP, Waasdorp M, Stoorvogel W, Wauben MH and t Hoen PA: Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. Nucleic acids research 40: 9272-9285, 2012.
72. Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, Liang M, Dittmar RL, Liu Y, Kohli M, Thibodeau SN, Boardman L and Wang L: Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMCGenomics 14: 319, 2013.
73. Crescitelli R, Lasser C, Szabo TG, Kittel A, Eldh M, Dianzani I, Buzas EI and Lotvall J: Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. JExtracellVesicles 2: 2013.
74. Jenjaroenpun P, Kremenska Y, Nair VM, Kremenskoy M, Joseph B and Kurochkin IV: Characterization of RNA in exosomes secreted by human breast cancer cell lines using next-generation sequencing. PeerJ 1: e201, 2013.
75. Lunavat TR, Cheng L, Kim DK, Bhadury J, Jang SC, Lasser C, Sharples RA, Lopez MD, Nilsson J, Gho YS, Hill AF and Lotvall J: Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells-Evidence of unique microRNA cargos. RNA biology 12: 810-823, 2015.
76. Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN, Pogosova-Agadjanyan EL, Morrissey C, Stirewalt DL, Hladik F, Yu EY, Higano CS and Tewari M: Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proceedings of the National Academy of Sciences of the United States of America 111: 14888-14893, 2014.
77. Holmgren L, Szeles A, Rajnavolgyi E, Folkman J, Klein G, Ernberg I, and Falk KI: Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood 93: 3956-3963, 1999.
78. Bergsmedh A, Szeles A, Henriksson M, Bratt A, Folkman MJ, Spetz AL and Holmgren L: Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proceedings of the National Academy of Sciences of the United States of America 98: 6407-6411, 2001.
79. Lazaro-Ibanez E, Sanz-Garcia A, Visakorpi T, Escobedo-Lucea C, Siljander P, Ayuso-Sacido A and Yliperttula M: Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes. Prostate 74: 1379-1390, 2014.
80. Logozzi M, de MA, Lugini L, Borghi M, Calabro L, Spada M, Perdicchio M, Marino ML, Federici C, Iessi E, Brambilla D, Venturi G, Lozupone F, Santinami M, Huber V, Maio M, Rivoltini L and Fais S: High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoSOne 4: e5219, 2009.
81. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD and Kloecker GH: Exosomal microRNA: a diagnostic marker for lung cancer. ClinLung Cancer 10: 42-46, 2009.
82. Rupp AK, Rupp C, Keller S, Brase JC, Ehehalt R, Fogel M, Moldenhauer G, Marme F, Sultmann H and Altevogt P: Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage. Gynecologic oncology 122: 437-446, 2011.
83. Galindo-Hernandez O, Villegas-Comonfort S, Candanedo F, Gonzalez-Vazquez MC, Chavez-Ocana S, Jimenez-Villanueva X, Sierra-Martinez M and Salazar EP: Elevated concentration of microvesicles isolated from peripheral blood in breast cancer patients. Archives of medical research 44: 208-214, 2013.
84. Khan S, Ferguson Bennit H, Turay D, Perez M, Mirshahidi S, Yuan Y, and Wall NR: Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC cancer 14: 176-185, 2014.
85. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA and Kalluri R: Cancer exosomes perform cellindependent microRNA biogenesis and promote tumorigenesis. Cancer cell 26: 707-721, 2014.
86. Cui Y, Zheng L, Jiang M, Jia R, Zhang X, Quan Q, Du G, Shen D, Zhao X, Sun W, Xu H and Huang L: Circulating microparticles in patients with coronary heart disease and its correlation with interleukin-6 and C-reactive protein. Molecular biology reports 40: 6437-6442, 2013.
87. Dragovic RA, Southcombe JH, Tannetta DS, Redman CW and Sargent IL: Multicolor flow cytometry and nanoparticle tracking analysis of extracellular vesicles in the plasma of normal pregnant and pre-eclamptic women. Biology of reproduction 89: 151, 2013.
88. Leonetti D, Reimund JM, Tesse A, Viennot S, Martinez MC, Bretagne AL and Andriantsitohaina R: Circulating microparticles from Crohn's disease patients cause endothelial and vascular dysfunctions. PLoS One 8: e73088, 2013.
89. Ogata N, Imaizumi M, Nomura S, Shozu A, Arichi M, Matsuoka M and Matsumura M: Increased levels of platelet-derived microparticles in patients with diabetic retinopathy. Diabetes research and clinical practice 68: 193-201, 2005.
90. Sarker S, Scholz-Romero K, Perez A, Illanes SE, Mitchell MD, Rice GE, and Salomon C: Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. Journal of translational medicine 12: 204, 2014.
91. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, and Rak J: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nature cell biology 10: 619-624, 2008.
92. Toth B, Nieuwland R, Liebhardt S, Ditsch N, Steinig K, Stieber P, Rank A, Gohring P, Thaler CJ, Friese K and Bauerfeind I: Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res 28: 1107-1112, 2008.
93. Menck K, Scharf C, Bleckmann A, Dyck L, Rost U, Wenzel D, Dhople VM, Siam L, Pukrop T, Binder C, and Klemm F: Tumor-derived microvesicles mediate human breast cancer invasion through differentially glycosylated EMMPRIN. J Mol Cell Biol 7: 143-153, 2015.
94. Eichelser C, Stuckrath I, Muller V, Milde-Langosch K, Wikman H, Pantel K, and Schwarzenbach H: Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget 5: 9650-9663, 2014.
95. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, and Kalluri R: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523: 177-182, 2015.
96. Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, and Diamandis EP: Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. BMC Cancer 13: 404, 2013.
97. Amorim M, Fernandes G, Oliveira P, Martins-de-Souza D, Dias-Neto E, and Nunes D: The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles. Proteomics 14: 1472-1479, 2014.
98. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Della Mina P, Menard S, Filipazzi P, Rivoltini L, Tagliabue E, and Pupa SM: Potential role of HER2-overexpressing exosomes in countering trastuzumabbased therapy. Journal of cellular physiology 227: 658-667, 2012.
99. O'Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM, McDonnell S, Crown J, Radomski MW, and O'Driscoll L: Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer 49: 1845-1859, 2013.
100. Harris DA, Patel SH, Gucek M, Hendrix A, Westbroek W, and Taraska JW: Exosomes released from breast cancer carcinomas stimulate cell movement. PloS one 10: e0117495, 2015.
101. Singh R, Pochampally R, Watabe K, Lu Z, and Mo YY: Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Molecular cancer 13: 256, 2014.
102. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor ST, Chin AR, Yen Y, Wang Y, Marcusson EG, Chu P, Wu J, Wu X, Li AX, Li Z, Gao H, Ren X, Boldin MP, Lin PC, and Wang SE: Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer cell 25: 501-515, 2014.
103. Tominaga N, Kosaka N, Ono M, Katsuda T, Yoshioka Y, Tamura K, Lotvall J, Nakagama H, and Ochiya T: Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nature communications 6: 6716, 2015.
104. Le MTN, Hamar P, Guo C, Basar E, Perdigao-Henriques R, Balaj L, and Lieberman J: miR-200-containing extracellular vesicles promote breast cancer metastasis. The Journal of clinical investigation 124: 5109-5128, 2014.
105. Suetsugu A, Honma K, Saji S, Moriwaki H, Ochiya T, and Hoffman RM: Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Advanced drug delivery reviews 65: 383-390, 2013.
106. Dutta S, Warshall C, Bandyopadhyay C, Dutta D, and Chandran B: Interactions between exosomes from breast cancer cells and primary mammary epithelial cells leads to generation of reactive oxygen species which induce DNA damage response, stabilization of p53 and autophagy in epithelial cells. PloS one 9: e97580, 2014.
107. Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J, Chow A, O'Connor ST, Li S, Chin AR, Somlo G, Palomares M, Li Z, Tremblay JR, Tsuyada A, Sun G, Reid MA, Wu X, Swiderski P, Ren X, Shi Y, Kong M, Zhong W, Chen Y, and Wang SE: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nature cell biology 17: 183-194, 2015.
108. Lima LG, Leal AC, Vargas G, Porto-Carreiro I, and Monteiro RQ: Intercellular transfer of tissue factor via the uptake of tumorderived microvesicles. Thrombosis research 132: 450-456, 2013.
109. Lv MM, Zhu XY, Chen WX, Zhong SL, Hu Q, Ma TF, Zhang J, Chen L, Tang JH, and Zhao JH: Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 35: 10773-10779, 2014.
110. Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y, Li H, Zhu X, Yao L, and Zhang J: Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast cancer research and treatment 147: 423-431, 2014.
111. Goler-Baron V and Assaraf YG: Structure and Function of ABCG2-Rich Extracellular Vesicles Mediating Multidrug Resistance. PloS one 6: e16007, 2011.
112. Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, Li C, Cong Y, Kimberly R, Grizzle WE, Falkson C, and Zhang HG: Tumor Exosomes Inhibit Differentiation of Bone Marrow Dendritic Cells. The Journal of Immunology 178: 6867-6875, 2007.
113. Clayton A and Tabi Z: Exosomes and the MICA-NKG2D system in cancer. Blood cells, molecules & diseases 34: 206-213, 2005.
114. Menck K, Klemm F, Gross JC, Pukrop T, Wenzel D, and Binder C: Induction and transport of Wnt 5a during macrophage-induced malignant invasion is mediated by two types of extracellular vesicles. Oncotarget 4: 2057-2066, 2013.
115. Chow A, Zhou W, Liu L, Fong MY, Champer J, Van Haute D, Chin AR, Ren X, Gugiu BG, Meng Z, Huang W, Ngo V, Kortylewski M, and Wang SE: Macrophage immunomodulation by breast cancerderived exosomes requires Toll-like receptor 2-mediated activation of NF-kappaB. Scientific reports 4: 5750, 2014.
116. Battke C, Ruiss R, Welsch U, Wimberger P, Lang S, Jochum S, and Zeidler R: Tumour exosomes inhibit binding of tumourreactive antibodies to tumour cells and reduce ADCC. Cancer immunology, immunotherapy: CII 60: 639-648, 2011.
117. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, and Rak J: Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proceedings of the National Academy of Sciences of the United States of America 106: 3794-3799, 2009.
118. Marleau AM, Chen CS, Joyce JA, and Tullis RH: Exosome removal as a therapeutic adjuvant in cancer. Journal of translational medicine 10: 134, 2012.